Scorpius Holdings, Inc. provided earnings guidance for the fourth quarter of 2023. Based upon a preliminary, unaudited review, the Company currently estimates revenue in the range of $3.4 million to $3.6 million for the fourth quarter of 2023. The increase in revenue reflects the completion of contract milestones primarily in the microbial facility and process development work.

Additionally, the Company estimates that operating loss will decline by over $3.3 million, or approximately 30%, as a result of primary completion of qualification and validation processes.